{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Singal AG"],"funding":["NCI NIH HHS"],"pagination":["1948-1951"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9722605"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["117(12)"],"pubmed_abstract":["Abdominal ultrasound, with or without alpha-fetoprotein, is the recommended strategy for hepatocellular carcinoma (HCC) surveillance but misses over one-third of HCC at an early stage. Emerging imaging modalities, including computed tomography and magnetic resonance imaging, have early data showing high sensitivity for early-stage HCC, but potential issues such as radiologic capacity, patient acceptance, cost-effectiveness, and need for validation in Western non-hepatitis B virus populations still need to be evaluated. Similarly, blood-based biomarker panels, including GALAD and liquid biopsy techniques, have shown promising data in phase II case-control studies and may concurrently help address issues of surveillance underuse; however, these tools require validation in phase III and IV co"],"journal":["The American journal of gastroenterology"],"pubmed_title":["Emerging Tools for Hepatocellular Carcinoma Surveillance."],"pmcid":["PMC9722605"],"funding_grant_id":["R01 CA222900","R01 CA212008","U01 CA230694"],"pubmed_authors":["Reig M","Singal AG","Villanueva A"],"additional_accession":[]},"is_claimable":false,"name":"Emerging Tools for Hepatocellular Carcinoma Surveillance.","description":"Abdominal ultrasound, with or without alpha-fetoprotein, is the recommended strategy for hepatocellular carcinoma (HCC) surveillance but misses over one-third of HCC at an early stage. Emerging imaging modalities, including computed tomography and magnetic resonance imaging, have early data showing high sensitivity for early-stage HCC, but potential issues such as radiologic capacity, patient acceptance, cost-effectiveness, and need for validation in Western non-hepatitis B virus populations still need to be evaluated. Similarly, blood-based biomarker panels, including GALAD and liquid biopsy techniques, have shown promising data in phase II case-control studies and may concurrently help address issues of surveillance underuse; however, these tools require validation in phase III and IV co","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2025-05-29T21:47:21.249Z","creation":"2025-05-29T21:47:21.249Z"},"accession":"S-EPMC9722605","cross_references":{"pubmed":["36114768"],"doi":["10.14309/ajg.0000000000002015"]}}